Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

HealthKit

- PMLiVE

FDA clears first-line use for J&J’s Darzalex

Front-line approval a milestone for blockbuster-tipped myeloma drug

- PMLiVE

J&J pays $140m upfront for cancer-busting virus firm BeneVir

The total value of the deal could go above $1bn if the biotech’s candidates perform well

- PMLiVE

J&J takes option on Theravance’s JAK drug in $1bn deal

TD-1473 has potential treating ulcerative colitis, Crohn’s and IBD patients

- PMLiVE

Smart watch epilepsy monitor cleared by FDA

Approval could potentially clear the way for insurers to reimburse its cost

- PMLiVE

Pfizer and IBM’s tech-enabled ‘Parkinson’s house’

Pharma firm looks to technology to help it unlock the doors to breakthrough treatments

- PMLiVE

Unsure on efficacy, NICE passes J&J’s Darzalex to CDF

The bone marrow cancer therapy is now temporarily approved as a fourth-line treatment

Apple launches Watch-powered atrial fibrillation study

The firm's Apple Heart Study app will see it collaborate with Stanford Medicine

Sharp rise in mobile health app numbers

US app stores show more than 318,500 now available

- PMLiVE

J&J files would-be prostate cancer blockbuster in US

Androgen receptor inhibitor achieves ‘significant’ MFS improvement over placebo

Roche - Basel

Roche and J&J picked for ‘revolutionary’ digital health pilot

Firms will line up alongside Apple, Fitbit, Samsung and Verily in FDA pre-certification programme

Roche and J&J picked for ‘revolutionary’ digital health pilot

Firms will line up alongside Apple, Fitbit, Samsung and Verily in FDA pre-certification programme

- PMLiVE

Xarelto no better than aspirin in secondary stroke study

The NOAC has 'very little' chance of showing overall benefit, says data monitoring committee

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links